Items tagged with Treatment

MSF Science (@MSFSci) Twitter Spaces event - Treating drug-resistant TB: the past, present and future (post)

On Friday 24th March, the MSF Science Twitter account will be hosting a Twitter Spaces event (a live audio discussion) on ‘Treating drug-resistant tuberculosis: the past, present and future’!

250,000 patients to benefit from free access to short-course TB prevention treatment across seven countries (post)

Johannesburg, 24 March 2023 – The Unitaid-funded IMPAACT4TB Consortium, led by the Aurum Institute, announced today that it will provide 250,000 patient courses of short course rifapentine-based preventive treatment regimens to seven countries to help prevent tuberculosis (TB). The patient courses will include the three-month 3HP regimen, and the even shorter 1HP, that is only taken for 28 days. This contribution is part of the Consortium’s ongoing efforts to end TB and improve global health outcomes. 

Significant step in fight against drug resistance in TB (post)

University of Otago researchers have discovered new ways to treat antibiotic-resistant strains of tuberculosis (TB), opening the door to new approaches for tackling the disease that kills about 4,000 people a day.

Revolution in MDR-TB treatment: Shorter all-oral regimens (post)

In a recent review published in the Open Forum Infectious Diseases journal, researchers reported on the evolution of multidrug-resistant tuberculosis (MDR-TB) therapy.

Webinar: TB treatment trial results in context for communities - materials now available online (post)

From the 2022 Union World Conference on Lung Health to the 2023 Conference on Retroviruses and Opportunistic Infections, several phase III treatment trials reported results with potential implications for TB policy and future research. On 14 March 2023, Treatment Action Group hosted a webinar where Dr. Jennifer Furin gave an overview of key results and how they fit into the larger TB policy and research landscapes.

Weekly rifapentine plus isoniazid for 3 months is safe for latent TB infection (post)

In those talking 3HP for LTBI, female sex, an age from 45 to 54 years, and use of concomitant medications were significantly linked to SDRs and discontinuing treatment.

How push from survivors and an HIV support group led to a cheaper TB drug (post)

Advocacy by patients led authorities to reject a patent application for bedaquiline, a drug that shortens treatment and has a higher success rate.

The Lancet Global Health: Open access TB research publications (post)

Novel drugs have potential for treating TB (post)

Tuberculosis, a bacterial lung infection, is one of the leading causes of death worldwide and is becoming increasingly resistant to antibacterial treatments. 

WHO BPaLM Accelerator Platform: to support the Call to Action for implementation of the shorter and more effective treatment for all people suffering from drug-resistant TB (post)

The World Health Organization (WHO)’s latest guidelines on drug-resistant TB treatment recommend rapid roll-out of the novel BPaLM regimen that has the potential to dramatically increase cure rates due to its high efficacy, allow broader access due to its lower cost and improve patient quality of life as this regimen is all-oral and significantly shorter than conventional treatment regimens. WHO and its partners have recently issued a Call to Action to call on governments and other stakeholders to accelerate the implementation of the novel, 6-month all-oral regimen for the treatment of drug-resistant TB.